同时给予膦甲酸钠和齐多夫定治疗人类免疫缺陷病毒感染的药代动力学（艾滋病临床试验组方案053）。
Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053).
作者信息
Aweeka F T, Gambertoglio J G, van der Horst C, Raasch R, Jacobson M A
机构信息
Division of Clinical Pharmacy, University of California, San Francisco 94143-0622.
出版信息
Antimicrob Agents Chemother. 1992 Aug;36(8):1773-8. doi: 10.1128/AAC.36.8.1773.
Abstract
Foscarnet and zidovudine (ZDV) pharmacokinetic parameters were not altered in five patients receiving 14 days of concomitant therapy. Foscarnet clearance in plasma averaged (+/- standard deviation) 0.16 +/- 0.03 and 0.13 +/- 0.05 liter/h/kg of body weight in the absence and presence of ZDV. ZDV parameters were also not significantly altered, with a mean (+/- standard deviation) oral clearance of 2.7 +/- 1.0 and 2.6 +/- 0.8 liter/h/kg for the 2 study days, respectively.
摘要
接受14天联合治疗的5名患者中，膦甲酸和齐多夫定（ZDV）的药代动力学参数未发生改变。在不存在和存在ZDV的情况下，血浆中膦甲酸清除率平均（±标准差）分别为0.16±0.03和0.13±0.05升/小时/千克体重。ZDV参数也未显著改变，两个研究日的平均（±标准差）口服清除率分别为2.7±1.0和2.6±0.8升/小时/千克。
相似文献
1
Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053).
Antimicrob Agents Chemother. 1992 Aug;36(8):1773-8. doi: 10.1128/AAC.36.8.1773.
2
Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.
Br J Clin Pharmacol. 1994 May;37(5):421-6. doi: 10.1111/j.1365-2125.1994.tb05708.x.
3
Oral and intravenous zidovudine pharmacokinetics: the effect of granulocyte-macrophage colony stimulating factor.
J Clin Pharmacol. 1995 Sep;35(9):856-64. doi: 10.1002/j.1552-4604.1995.tb04130.x.
4
Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062).
Antimicrob Agents Chemother. 1995 Dec;39(12):2732-7. doi: 10.1128/AAC.39.12.2732.
5
Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.
Antimicrob Agents Chemother. 1992 Sep;36(9):1821-4. doi: 10.1128/AAC.36.9.1821.
6
Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
Antimicrob Agents Chemother. 1989 May;33(5):742-5. doi: 10.1128/AAC.33.5.742.
7
Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus.
Antimicrob Agents Chemother. 1996 Jan;40(1):230-3. doi: 10.1128/AAC.40.1.230.
8
Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients.
Eur J Med Res. 1997 Sep 29;2(9):377-83.
9
Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS.
Antimicrob Agents Chemother. 1997 Jun;41(6):1226-30. doi: 10.1128/AAC.41.6.1226.
10
In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG Protocol 053).
J Infect Dis. 1991 Jun;163(6):1219-22. doi: 10.1093/infdis/163.6.1219.
引用本文的文献
1
Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV, Part II: Drugs Licensed Before 2005.
Clin Pharmacokinet. 2024 Dec;63(12):1655-1666. doi: 10.1007/s40262-024-01441-9. Epub 2024 Nov 14.
2
Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.
Paediatr Drugs. 2002;4(8):515-53. doi: 10.2165/00128072-200204080-00004.
3
Pharmacokinetic interaction of megestrol acetate with zidovudine in human immunodeficiency virus-infected patients.
Antimicrob Agents Chemother. 1997 Nov;41(11):2480-3. doi: 10.1128/AAC.41.11.2480.
4
Drug interactions with antiviral drugs.
Clin Pharmacokinet. 1996 May;30(5):385-401. doi: 10.2165/00003088-199630050-00005.
5
Penetration of foscarnet into cerebrospinal fluid of AIDS patients.
Antimicrob Agents Chemother. 1993 Sep;37(9):1777-80. doi: 10.1128/AAC.37.9.1777.
6
Foscarnet for suppression of human immunodeficiency virus replication.
Antimicrob Agents Chemother. 1994 Mar;38(3):604-7. doi: 10.1128/AAC.38.3.604.
7
Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Drugs. 1993 Sep;46(3):515-578. doi: 10.2165/00003495-199346030-00010.
8
Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).
Drugs. 1993 May;45(5):637-53. doi: 10.2165/00003495-199345050-00002.
9
Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
Drugs. 1994 Aug;48(2):199-226. doi: 10.2165/00003495-199448020-00007.
本文引用的文献
1
Simultaneous quantification of zidovudine and its glucuronide in serum by high-performance liquid chromatography.
J Chromatogr. 1988 Sep 23;431(1):123-33. doi: 10.1016/s0378-4347(00)83075-3.
2
Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus.
Clin Pharmacol Ther. 1988 Jul;44(1):65-73. doi: 10.1038/clpt.1988.114.
3
Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.
J Infect Dis. 1988 Oct;158(4):862-5.
4
Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis.
Clin Pharmacol Ther. 1989 Aug;46(2):190-7. doi: 10.1038/clpt.1989.125.
5
Clinical pharmacokinetics of zidovudine. An overview of current data.
Clin Pharmacokinet. 1989 Jul;17(1):1-9. doi: 10.2165/00003088-198917010-00001.
6
Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
Antimicrob Agents Chemother. 1989 May;33(5):742-5. doi: 10.1128/AAC.33.5.742.
7
Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
Antimicrob Agents Chemother. 1989 May;33(5):736-41. doi: 10.1128/AAC.33.5.736.
8
Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro.
Antimicrob Agents Chemother. 1989 May;33(5):663-9. doi: 10.1128/AAC.33.5.663.
9
Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.
Antimicrob Agents Chemother. 1989 Jul;33(7):1023-31. doi: 10.1128/AAC.33.7.1023.
10
Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.
Antimicrob Agents Chemother. 1989 May;33(5):778-80. doi: 10.1128/AAC.33.5.778.
Zotero 插件